Our Current Trials Recruiting Now for Rheumatoid Arthritis

Rheumatoid Arthritis

RA Clinical Trial

Rheumatoid Arthritis (RA) is an autoimmune disease that causes pain and swelling of the joints. During RA, the immune system attacks it's own tissues targeting the joints and causing inflammation and joint damage.

Servatus Ltd has developed a Live Biotherapeutic Product (LBP) to treat RA. The clincial trial is currently being conducted through the Rheumatoid Research Unit on the Sunshine Coast.

A primary research focus for Servatus is the development of Live Biotherapeutics (micro-organisms) which can be used to prevent or treat disease. SVT-6A4710 is an LBP which has been developed to treat Rheumatoid Arthritis.

** In order to be eligible to participate in the study, you must meet all of the following requirements:

  • Aged 18 - 80 years old;

  • Be diagnosed with RA;

  • Currently experiencing joint pain, swelling, and tenderness in several joints;

  • Not currently taking biologic disease-modifying, anti-rheumatic drugs (DMARD) to treat your condition.

To express interest in participating in this trial, please complete this short questionnaire:

Click here to apply and check your eligibility.

Ensure your contact details are provided, so our team can get in touch with you. If you have any questions about this study, you can email us at clinical.research@servatus.com.au

This study has been approved by an independent Human Research Ethics Committee.

Helicobacter pylori - RECRUITING NOW!

H. pylori Clinical Trial

H. pylori is a bacterial infection that occurs when H. pylori bacteria (grouped as a class 1 carcinogen) bind to the lining of the stomach wall or the first part of the small intestine. In some people this can lead to chronic inflammation of the stomach lining, which left untreated may lead to duodenal ulcer and gastric cancer.

H. Pylori is estimated to have infected more than half of the worldwide population, and most people are unaware they have the infection. Only about 15% of infected individuals will develop symptoms (chronic inflammation of the stomach lining) which left untreated may lead to duodenal ulcer and gastric cancer.

The most widely used treatment is a combination of a proton pump inhibitor (PPI) and the two different antibiotics. This treatment is not successful in eradicating H. pylori infection in all patients and many patients experience unwanted side effects to these medications. Development of antibiotic resistance can also cause the infection to persist for long periods of time, increasing the risk of complications.

Servatus Ltd has developed a Live Biotherapeutic Product SVT-1C4610 to treat H. pylori infection. The clinical trial is currently being conducted through the Department of Gastroenterology & Hepatology at the Princess Alexandra Hospital, Brisbane.

In order to be eligible to participate in the study, you must meet all of the following requirements:

  • Aged 18 or older;

  • Test positive for H. pylori infection;

  • Able to attend the Princess Alexandra Hospital as required;

  • Otherwise medically healthy.

RECRUITING NOW! To express interest in participating in this trial, please complete this short questionnaire:

Click here to apply and check your eligibility.

Ensure your contact details are provided, so our team can get in touch with you. If you have any questions about this study, you can email us at clinical.research@servatus.com.au

This study has been approved by an independent Human Research Ethics Committee.